KRAS and neoplasm: Thus, while KRAS G12C inhibitors represent a significant milestone in precision oncology, their impact on OSCC is currently limited, emphasizing the need for more precise molecular profiling to uncover new therapeutic vulnerabilities within the RAS signaling axis in this tumor type [85,86,88].